2026年10月16日星期五
M
Atlante Universale
Notizie flash globali
[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet

[Correspondence] Optimising standard of care in non-small-cell lung cancer trials – Authors’ reply

Fonte 柳叶刀 LancetAdesso
Sintesi del contenuto

We thank Emma D A Wagener and Wouter H van Geffen for emphasising the importance of comparator selection. We agree that pembrolizumab plus platinum-based chemo…

Questo sito fornisce solo titoli e indici di riepilogo; il contenuto completo e i diritti d'autore appartengono all'editore originale. Clicca sul link all'articolo originale per leggerlo.

Vai all'articolo originale
Canale di appartenenza
Salute
Regione di appartenenza
Regno Unito
Lingua originale
English
Numero di voce
health-514fc802

Comments 0 comments

No comments yet. Be the first.

[Correspondence] Optimising standard of care in non-small-cell lung cancer trials – Authors’ reply · Atlante Universale